Clinical Trial

Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients

Study acronym: ROSUBREAST
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based chemotherapy. A total of 400 participants will be randomly assigned to receive either rosuvastatin or placebo for 12 months. The main goal is to determine whether rosuvastatin can prevent cancer treatment-related cardiac dysfunction (CTRCD), defined as a significant drop in heart pumping function. The study will also assess changes in cardiac strain, blood biomarkers, symptoms of heart failure, quality of life, and possible side effects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Trial Details
NCT Number NCT07254221
Lead Sponsor Shiraz University of Medical Sciences
Conditions Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Anthracycline-induced Cardiotoxicity
Enrollment 400 participants
Start Date 2026-02-01
Primary Completion 2028-04-21 (estimated)
Study Completion 2028-04-21 (estimated)
Updated on ClinicalTrials.gov 2025-12-10